You cannot select more than 25 topics
Topics must start with a letter or number, can include dashes ('-') and can be up to 35 characters long.
40 lines
1.9 KiB
TeX
40 lines
1.9 KiB
TeX
\documentclass[../Main.tex]{subfiles}
|
|
\graphicspath{{\subfix{Assets/img/}}}
|
|
|
|
\begin{document}
|
|
Identifying commercial impediments to successfully completing
|
|
clinical trials in otherwise capable pharmaceuticals will hopefully
|
|
lead to a more robust and competitive pharmaceutical market.
|
|
Although the current state of this research is insufficient to draw robust
|
|
conclusions, these early results suggest that delaying the close of
|
|
enrollment periods reduces the probability of termination of a trial.
|
|
|
|
The successful completion of Phase III clinical trials is crucial for
|
|
bringing new treatments to market.
|
|
This research provides insights into how enrollment management
|
|
impacts trial outcomes.
|
|
While the preliminary results suggest that delaying the close of enrollment
|
|
periods may reduce termination probability, the analysis
|
|
reveals significant variation across disease categories and highlights
|
|
important methodological challenges.
|
|
The primary limitation that must be addressed before drawing a strong conclusion
|
|
is that of insufficient data.
|
|
This takes two forms.
|
|
The first is the small sample size.
|
|
To overcome this requires an improved data matching
|
|
approach and a revised data scraper.
|
|
The second is creating a model of enrollment that can be used to address
|
|
the causal identification issue from the joint determination of
|
|
enrollment statuses and elapsed durations of trials.
|
|
|
|
Despite these limitations, this work establishes a framework for analyzing
|
|
operational versus strategic factors in clinical trial completion.
|
|
The approach developed here can be extended with additional data to
|
|
provide more definitive guidance on enrollment management strategies.
|
|
Further research in this direction could help reduce operational
|
|
barriers to trial completion or estimating the impact policies may have through
|
|
operational channels.
|
|
Ultimately this work will hopefully support more efficient drug
|
|
development and increased market competition.
|
|
\end{document}
|